Related Experiment Video
Updated: Apr 4, 2026
07:09
The Sciatic Nerve Cuffing Model of Neuropathic Pain in Mice
Published on: July 16, 2014
49.7K
Inhaled Cannabis for Chronic Neuropathic Pain: A Meta-analysis of Individual Patient Data
Michael H Andreae1, George M Carter2, Naum Shaparin1
1Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York.
The Journal of Pain
|September 13, 2015
Summary
Inhaled cannabis may offer short-term pain relief for neuropathic pain patients. This treatment benefits approximately 1 in 5 to 6 individuals, according to a meta-analysis of randomized trials.
Area of Science:
- Neurology
- Pain Management
- Pharmacology
Background:
- Chronic neuropathic pain is a prevalent peripheral nervous system condition, often underdiagnosed and challenging to manage.
- Inhaled cannabis is being explored as a potential treatment for chronic neuropathic pain.
Purpose of the Study:
- To systematically review and meta-analyze existing evidence on the efficacy of inhaled cannabis for chronic neuropathic pain.
Main Methods:
- A systematic review and individual patient data meta-analysis were conducted.
- Searched multiple databases (Cochrane Central, PubMed, EMBASE, AMED) for randomized controlled trials comparing inhaled cannabis to placebo.
- Utilized a hierarchical random-effects Bayesian responder model for data synthesis.
Main Results:
- Evidence synthesis from 5 randomized controlled trials involving 178 participants indicated that inhaled cannabis provides short-term pain reduction.
- The number needed to treat was calculated as 5.6, suggesting that 1 in 5 to 6 patients experience relief.
- Bayesian analysis showed a high probability of effect (99.7%).
Conclusions:
- Inhaled cannabis may offer short-term relief for a subset of patients with neuropathic pain.
- Limitations include a small number of studies, short follow-up periods, and participant attrition.
- Further pragmatic trials are recommended to assess long-term benefits and risks.
